Calls for Proposals Overseas FY 2022 [Pre-announcement] The Public Offering for the 3rd Proposal of Moonshot Research and Development Program
|Status of Grants/Funding Opportunities||Pre-announcement|
|R&D phase||Basic Study, Applied Study, Nonclinical Study/Pre-clinical Study, Clinical Study, Clinical Trials, None|
|Key Fields||Moonshot Research and Development Program|
|Submission Deadline||Early September, 2022|
Public offering content
AMED will make the public offering for the 3rd proposal of “Moonshot R&D program / Realization of sustainable care systems to overcome major diseases by 2040 for enjoying one’s life with relief and release from health concerns until 100 years old” in the early of March.
Sub-titles of the public offering
※The public offering is divided into two proposals ,that is,the 2nd proposal and the 3rd proposal, because they have different viewpoints and application guidelines.
※This page contains information about the 3rd proposal.
※For more information about the 2nd proposal, please refer to the separate page (FY 2022 [Pre-announcement] The Public Offering for the 2nd Proposal of Moonshot Research and Development Program).
[The 2nd proposal]
- Moonshot Goal 7: The research and development on Target 2 (Realization of medical networks accessible for anyone from anywhere in the world)
- Moonshot Goal 7: The research and development towards novel approach (Example : Intestinal flora, etc.)
[The 3rd proposal]
- Moonshot Goal 7: The research and development towards “The society with zero-cancer” through the Japan-U.S. Partnership.
※The subtitles are provisional, and may be changed.
※Concerning the details of the public offering , please confirm the application guideline after the start of the public offering.
※AMED cannot respond the inquiries regarding the public offering until the starts of the offering.
Background and aims
Headquarters for Healthcare Policy have determined to promote challenging R&D program called Moonshot (hereinafter referred to as “MS”), based on ideas that are not mere extension of conventional technology to create disruptive innovation in Japan.
Based on the MS R&D program, AMED has established the fund as the research promotion agency that conducts the operations for the R&D, and promoted challenging R&D towards the realization of the R&D concepts in order to achieve the MS goal determined by Headquarters for Healthcare Policy.
Public invitation briefing
Due to the pandemic of COVID-19, AMED will not hold the briefing session for the public offering.
How to Apply
For the application, the principal investigator and members in the research team need to be registered on e-Rad with their organization name.
In case the registration process takes longer time, the registration needs to be completed at least two weeks before the deadline.
Last updated 02/24/22